An open-label phase 1b/2 study assessing the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma

This study is open to men and women aged 18 or older who have been diagnosed with metastatic pancreatic ductal adenocarcinoma. This means the cancer began in the ducts of the pancreas and has already spread to other areas of the body.

To join, participants usually need to be well enough to carry out everyday activities, such as looking after themselves and walking around. Doctors will also check that your vital organs, such as your liver, kidneys, and bone marrow, are working well enough to receive treatment safely.

You may not be able to take part if you have certain other serious health issues, severe active infections, or if you have had specific cancer treatments very recently. A hospital trial doctor will review your full medical history and recent test results to see if the trial is right for you.

If you take part, you will receive treatment through a drip into a vein at the hospital clinic. This includes mitazalimab along with standard chemotherapy drugs given in regular treatment cycles. You will visit the hospital frequently at first for treatment, physical checks, and blood tests so the team can monitor how you feel and watch for side effects. Every few weeks, you will have imaging scans (such as CT scans) to check if your tumours are shrinking or staying the same. Treatment usually continues for as long as it is helping and side effects remain manageable. Afterwards, the team will continue to check on your health through follow-up visits or phone calls.